This is a working overview of peptide acylation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-14 and is reviewed periodically as new material appears.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Isoguanine and isocytosine, which have their amine and ketone inverted compared to standard guanine and cytosine. They are not used probably as tautomers are problematic for base pairing, but isoC and isoG can be amplified correctly with PCR even in the presence of the 4 canonical bases. Diaminopyrimidine and xanthine, which bind like 2-aminoadenine and thymine but with inverted structures. This pair is not used as xanthine is a deamination product.
== Pharmacokinetics == Most wrinkle fillers are temporary because they are eventually metabolized by the body. Some people may need more than one injection to achieve the wrinkle-smoothing effect. The effect lasts for about six months. Results depend on health of the skin, skill of the health care provider, and the type of filler used. Regardless of material (whether synthetic or organic) filler duration is highly dependent on amount of activity in the body area where it is injected. Exercise and high intensity activities such as manual labor can stimulate blood flow and shorten the lifespan of fillers.
==== Agitation of hydrophilic primer or adhesive during application ==== Besides having adequate dentinal moisture, agitation of the primers during application of two-step etch-and-rinse adhesives may be critical for optimal penetration into the demineralized collagen fibres. It also may aid the evaporation of residual water in the adhesive and hybrid layers, thus preventing nano leakage. In a clinical trial comparing the performance of Prime & Bond NT using no rubbing action, slight rubbing action and vigorous rubbing action in the restoration of NCCLs, 92.5% of restorations in vigorous rubbing action group were found to retain after 24 months of clinical service. For the other two groups, the retention rates of the restoration were slightly lower, at 82.5%.
Sources: en.wikipedia.org
Following the end of the Chadian-Libyan conflict, relations with Libya were normalised in 1994. Starting in the mid-1990s, the AAT started to grow slowly but steadily. In 1995, two second-hand Aérospatiale Alouette IIIs were bought from the Netherlands. Two Mil Mi-24Ds and one Mil Mi-17 were also purchased in the late 1990s. Libya donated two Antonov An-26s in the same period, and two SIAI-Marchetti SF.260s in 2006. Two Mi-24Vs were delivered from Ukraine in 2000, as well as four Mi-17s in 2001 and 2006. Four more Mi-24Vs were delivered from the same source in 2007–2008. The expansion of the AAT in this period was fuelled by royalties from oil exports that started in the mid-2000s. In 2005, one of the two PC-7s donated by France in the 1980s was overhauled by the company Griffon Aerospace, which also bought another on the civilian market in the United States. The same company then purchased a single Pilatus PC-9 directly from Swiss manufacturer Pilatus Aircraft, and contracted around 50 French, Algerian and Mexican personnel to serve in the AAT. Griffon Aerospace then proceeded to modify one Mi-17V-5, three Mi-24Vs and the PC-9 with hardpoints allowing them to carry Mark 81 and Mark 82 bombs, sourced from Pakistan. The three Mi-24Vs were also made compatible with night-vision goggles. The weaponisation of the PC-9 caused a scandal in Switzerland, as the Chadian government had promised it would not be used in a combat role. This affair marked the end of Griffon Aerospace's work in Chad, and all of its employees left the country by March 2008.
The laboratory mouse or lab mouse is a small mammal of the order Rodentia which is bred and used for scientific research or feeders for certain pets. Laboratory animal sources for these mice are usually of the species Mus musculus. They are the most commonly used mammalian research model and are used for research in genetics, physiology, psychology, medicine and other scientific disciplines. Mice belong to the Euarchontoglires clade, which includes humans. This close relationship, the associated high homology with humans, their ease of maintenance and handling, and their high reproduction rate make mice particularly suitable models for human-oriented research. The laboratory mouse genome has been sequenced, and many mouse genes have human homologues. Lab mice are sold at pet stores for snake food and can also be kept as pets. Other mouse species sometimes used in laboratory research include two American species, the white-footed mouse (Peromyscus leucopus) and the eastern deer mouse (Peromyscus maniculatus).
Gorky Park (officially the Central Park of Culture and Rest), named after writer Maxim Gorky, was founded in 1928. The main area (689,000 square meters or 170 acres) along the Moskva River contains estrades (raised platforms), children's attractions—including the Observation Wheel, as well as ponds with boats and water bicycles—dancing, tennis courts, and other sports facilities. Gorky Park borders the Neskuchny Garden (408,000 square meters or 101 acres), the oldest park in Moscow and a former imperial residence, created as a result of integrating three estates during the 18th century. The garden features the Green Theater, one of the largest open amphitheaters in Europe, able to contain up to 15 thousand people. Several parks include a section known as a "Park of Culture and Rest", sometimes alongside a wilder area. (Such parks include Izmaylovsky, Fili, and Sokolniki.) Some parks are designated Forest Parks (lesopark).
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.